These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Certolizumab pegol: new drug. As a last resort in Crohn's disease: continue to use other TNF alpha inhibitors. Prescrire Int; 2009 Jun; 18(101):108-10. PubMed ID: 19637418 [Abstract] [Full Text] [Related]
9. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984 [Abstract] [Full Text] [Related]
10. First case report of adalimumab-induced psoriasis in Crohn's disease. Harris MD, Richards R. Am J Gastroenterol; 2009 Mar; 104(3):792-3. PubMed ID: 19262532 [No Abstract] [Full Text] [Related]
11. TNF-α inhibitor (adalimumab) induced psoriasis: a case report. Al-Mutairi A, Elkashlan M, Al-Fayed HM, Swayed M. Australas J Dermatol; 2012 May; 53(2):157. PubMed ID: 22571571 [No Abstract] [Full Text] [Related]